PT-141 Bremelanotide Nasal Spray — Central-Mechanism Sexual Health Support

PT-141 activates melanocortin 3 (MC3R) and melanocortin 4 (MC4R) receptors in the brain — particularly the hypothalamus — to produce its sexual effects through:

• Dopaminergic Activation: Stimulates dopamine release in reward and motivation circuits, directly elevating libido and sexual interest independent of vascular response.
• Nitric Oxide / Oxytocinergic Pathways: Triggers nitric oxide release which relaxes penile smooth muscle and increases blood flow in men, while also stimulating oxytocin signaling linked to arousal and bonding.
• MC4R-Dependent Erection: MC4R activation in the hypothalamic paraventricular nucleus stimulates pro-erectile pathways, offering efficacy in men who are non-responders to PDE5 inhibitors due to underlying vascular or neurological causes.

Unlike sildenafil or tadalafil (PDE5 inhibitors), which require sexual stimulation to act on peripheral vascular tissue, PT-141 acts centrally, triggering the brain's own sexual desire circuitry. This produces desire and arousal even in the absence of external stimulation.

Intranasal administration bypasses hepatic first-pass metabolism. Nasal mucosal absorption allows the peptide to cross the blood-brain barrier via olfactory bulb pathways, with peak plasma levels typically reached within 30–60 minutes.

Women:

• Hypoactive Sexual Desire Disorder (HSDD) — the primary studied indication (FDA-approved subcutaneous form: Vyleesi® 1.75 mg)
• Female Sexual Arousal Disorder (FSAD)
• Premenopausal women with general decreased libido not explained by relationship or psychological factors

Men:

• Erectile dysfunction in men who are non-responders to PDE5 inhibitors (Viagra, Cialis)
• Psychogenic erectile dysfunction
• Low libido / hypoactive desire not addressed by testosterone replacement alone

Compared to PDE5 Inhibitors: PT-141 is particularly valuable where vascular mechanisms are intact but libido/desire is the primary impairment, or where PDE5 inhibitors are contraindicated, ineffective, or cause undesirable side effects.

Compounded intranasal PT-141 is off-label. The only FDA-approved bremelanotide product (Vyleesi®) is a subcutaneous injection for premenopausal women with HSDD.

Contraindications:

• Uncontrolled hypertension (systolic ≥130 mmHg) or known cardiovascular disease — PT-141 causes a transient increase of ~6 mmHg systolic BP and ~3 mmHg diastolic BP peaking at 4 hours
• Pregnancy — known fetal harm; stop immediately if pregnancy occurs and notify physician
• Known hypersensitivity to bremelanotide or any formulation component
• Severe renal impairment (CrCl <30 mL/min) or severe hepatic impairment
• Active cardiovascular disease or history of high-risk cardiac events

Common Side Effects (Incidence >4%):

• Nausea — most common (~40%); usually transient; pre-medicating with an antiemetic (e.g., ondansetron) reduces severity
• Flushing (~20%) — warmth, redness in face and upper body
• Headache (~11%) — typically mild to moderate, self-limiting
• Injection/nasal site reactions (~13%) — including nasal burning or irritation with intranasal route
• Vomiting (~5%) — particularly at higher doses

Less Common: Fatigue, dizziness, mild nasal congestion, transient hyperpigmentation of face/gums (with daily use), blurred vision, palpitations.

Blood Pressure Monitoring: PT-141 is contraindicated in patients with uncontrolled hypertension. Monitor BP during initial treatment. Not for use with concomitant nitrates.

Breastfeeding: Safety not established; avoid use.

To reduce nausea: start at lowest dose, titrate slowly, and consider antiemetic premedication. Nausea typically subsides with subsequent doses as tolerance develops.

• Refrigerate at 2°C to 8°C (36°F to 46°F)
• The beyond-use date (BUD) is 30 days from the date of compounding. Discard after this date.
• Protect from light; store in original packaging
• Do not freeze; discard if product has been frozen
• Each 10 mL bottle at 2 mg/mL contains approximately 100 sprays (0.1 mL/spray = 0.2 mg per spray)
• Keep out of reach of children
• The medicine should be fine for 5 days from the shipping date at temperatures up to 105 degrees Fahrenheit.

How does PT-141 differ from Viagra or Cialis?

PDE5 inhibitors (Viagra, Cialis) work by increasing blood flow to the genitals in response to sexual stimulation — they do not affect libido or desire. PT-141 works in the brain, activating desire and arousal pathways directly. It is particularly useful for patients where desire, not vascular response, is the primary issue, or for those who do not respond to PDE5 inhibitors.

How long before activity should I take it?

Administer 30–60 minutes before anticipated sexual activity. Nasal absorption is faster than injection, with peak effects typically within 45 minutes and lasting 6–12 hours.

I'm nauseous after taking it. What can I do?

Nausea is the most common side effect. Start with the lowest dose (0.5 mg). Pre-medicating with an OTC antiemetic 30 minutes before dosing significantly reduces nausea. Eat a light meal beforehand. Nausea typically decreases with repeated use as your body adjusts.

How often can I use it?

No more than once every 24 hours. Monthly use should not exceed 8 doses to reduce the risk of receptor tolerance and side effects.

Can I take it with my antihypertensive medication?

PT-141 causes a transient increase in blood pressure. If you are on antihypertensive medication, inform your prescriber. It is contraindicated in uncontrolled hypertension (≥130/80 mmHg untreated). Monitor your blood pressure during initial use.

Is it safe for women?

PT-141 was FDA-approved (as injectable Vyleesi) specifically for premenopausal women with HSDD. The intranasal compounded form is off-label. It should not be used during pregnancy as it may cause fetal harm.